Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Blastic natural killer (NK)-cell leukemia/lymphoma is a rare and aggressive hematologic neoplasm.
• It primarily affects elderly individuals and is characterized by blastic morphology and NK-cell immunophenotype.
• Diagnosis relies on specific morphological and immunophenotypic features, excluding Epstein-Barr virus association.

Observation:

• This report details a case of blastic NK-cell leukemia/lymphoma presenting with overt leukemia at diagnosis.
• The patient initially achieved a complete response following cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy.
• However, the patient experienced a relapse shortly after and succumbed to disease progression.

Findings:

• Blastic NK-cell leukemia/lymphoma demonstrates aggressive behavior and a propensity for relapse.
• CHOP chemotherapy can induce remission but may not provide durable long-term control.
• The case underscores the challenging clinical course and limited treatment options for this malignancy.

Implications:

• Further research into novel therapeutic strategies is crucial for improving outcomes in blastic NK-cell leukemia/lymphoma.
• Early diagnosis and aggressive treatment approaches are essential for managing this aggressive neoplasm.
• Understanding the biology of NK-cell leukemia/lymphoma may lead to targeted therapies.